Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
Public ClinicalTrials.gov record NCT04379050. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to continue testing whether ABBV-951 is safe, effective, and tolerable in participants with Parkinson's disease after completion of the parent study M15-741. ABBV-951 is an investigational (unapproved) drug containing levodopa phosphate/carbidopa phosphate (LDP/CDP) given as infusion under the skin for the treatment of Parkinson's Disease. Participants who have successfully completed M15-741 study will immediately enter this study's treatment period to continue receiving ABBV-951. Adult participants with advanced PD will be enrolled. Approximately 130 adult participants will be enrolled in the study at approximately 65 sites worldwide. Participants will receive continuous subcutaneous infusion (CSCI) of ABBV-951 for 24 hours daily during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular clinic visits and have remote assessments completed via phone calls during the course of the study. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
Study identification
- NCT ID
- NCT04379050
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2020 (Actual)
- Primary completion
- Apr 17, 2026 (Actual)
- Completion
- Apr 17, 2026 (Actual)
- Last update posted
- May 13, 2026
2020 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham - Main /ID# 215597 | Birmingham | Alabama | 35233 | — |
| Banner Sun Health Research Institute /ID# 215579 | Sun City | Arizona | 85351 | — |
| University of Colorado Hospital /ID# 215625 | Aurora | Colorado | 80045 | — |
| Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 215412 | Boca Raton | Florida | 33486 | — |
| Indiana Clinical Research Cent /ID# 216490 | Indianapolis | Indiana | 46202 | — |
| Univ Kansas Med Ctr /ID# 215624 | Kansas City | Kansas | 66160 | — |
| Washington University-School of Medicine /ID# 215472 | St Louis | Missouri | 63110 | — |
| Dartmouth-Hitchcock Medical Center /ID# 216834 | Lebanon | New Hampshire | 03756 | — |
| M3 Wake Research - Raleigh /ID# 215596 | Raleigh | North Carolina | 27612-8106 | — |
| Legacy Medical Group - Neurology /ID# 215536 | Portland | Oregon | 97232-2003 | — |
| Baylor College of Medicine /ID# 215401 | Houston | Texas | 77030 | — |
| Central Texas Neurology Consul /ID# 217013 | Round Rock | Texas | 78681 | — |
| Univ Texas HSC San Antonio /ID# 215400 | San Antonio | Texas | 78229-3901 | — |
| Booth Gardner Parkinson's Care Center /ID# 215535 | Kirkland | Washington | 98034-3029 | — |
| Inland Northwest Research /ID# 215533 | Spokane | Washington | 99202-1342 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04379050, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2026 · Synced Nov 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04379050 live on ClinicalTrials.gov.